UBS Group reissued their neutral rating on shares of Shire (LON:SHP) in a research report released on Thursday, investing.thisismoney.co.uk reports.
A number of other analysts also recently issued reports on SHP. Keefe, Bruyette & Woods reiterated a buy rating and issued a GBX 4,640 ($60.63) price objective on shares of Shire in a report on Thursday, November 22nd. Barclays reiterated an equal weight rating on shares of Shire in a report on Monday, September 17th. Kepler Capital Markets lifted their price objective on shares of Shire from GBX 4,550 ($59.45) to GBX 4,640 ($60.63) and gave the company a buy rating in a report on Thursday, November 22nd. Credit Suisse Group restated an outperform rating on shares of Shire in a report on Thursday, November 1st. Finally, Deutsche Bank restated a buy rating on shares of Shire in a report on Friday, November 2nd. Seven investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Shire currently has an average rating of Buy and an average target price of GBX 4,771.80 ($62.35).
Shares of LON SHP traded down GBX 77 ($1.01) during midday trading on Thursday, reaching GBX 4,533 ($59.23). The company’s stock had a trading volume of 2,615,296 shares, compared to its average volume of 3,140,000. Shire has a fifty-two week low of GBX 2,940.50 ($38.42) and a fifty-two week high of GBX 5,021 ($65.61).
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Recommended Story: What is Liquidity?
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.